StockNews.AI
ACAD
StockNews.AI
2 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

1. Pomerantz LLP is investigating potential securities fraud by ACADIA Pharmaceuticals. 2. ACAD announced disappointing Phase 3 trial results for intranasal carbetocin. 3. Stock fell 9.92% following the negative trial outcome announcement. 4. No further investigation into intranasal carbetocin is planned by ACAD. 5. Investors can join a class action related to these claims.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The lack of efficacy in clinical trials typically results in significant investor loss, as seen with similar pharma stocks that have faced trial failures—often leading to long-term value erosion.

How important is it?

The article discusses claims of securities fraud coupled with a major trial failure, directly impacting investor confidence and ACAD’s stock price.

Why Short Term?

Immediate reactions to trial results and investigations usually result in quick stock volatility and potential sell-offs.

Related Companies

VRTXSGENSAGE
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 24, 2025, Acadia issued a press release "announc[ing] top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS)."  The press release disclosed that the drug "did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), nor was there separation from placebo on any secondary endpoint."  Acadia's Head of Research and Development stated that, "given these results, we do not intend to investigate intranasal carbetocin any further."  On this news, Acadia's stock price fell $2.34 per share, or 9.92%, to close at $21.26 per share on September 24, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.   CONTACT: Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News